Amphastar Pharmaceuticals (AMPH) Return on Invested Capital (2014 - 2026)

Amphastar Pharmaceuticals' Return on Invested Capital history runs 13 years deep, the most recent figure standing at 0.26% for Q1 2026.

• On a quarterly basis, Return on Invested Capital fell 124.0% year-over-year to 0.26% in Q1 2026; TTM through Mar 2026 was 0.26%, a 124.0% decrease from a year earlier, with the FY2025 full-year figure at 1.47%, down 370.0% from the prior year.
• Return on Invested Capital fell to 0.26% in Q1 2026 per AMPH's latest filing, from 0.46% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 1.5% in Q1 2025 and bottomed at 6.51% in Q3 2024.
• The 5-year median for Return on Invested Capital is 0.1% (2022), against an average of 0.08%.
• Across the five-year window, Return on Invested Capital slumped 659 bps in 2024 and surged 714 bps in 2025, its largest moves.
• Year by year, Return on Invested Capital stood at 0.1% in 2022, then jumped by 355 bps to 0.46% in 2023, then surged by 199 bps to 1.37% in 2024, then plunged by 67 bps to 0.46% in 2025, then plunged by 43 bps to 0.26% in 2026.
• Per Business Quant, the three latest AMPH Return on Invested Capital figures stand at 0.26% (Q1 2026), 0.46% (Q4 2025), and 0.63% (Q3 2025).